Immatics' vaccine prolongs survival in renal cell cancer
13:05 EDT 30 Jul 2012 | SCRIP
Immatics' lead cancer vaccine IMA901 can prolong survival times in renal cell carcinoma patients whose immune system responds to more than one of its ten constituent tumour-associated peptides (TUMAPs), show Phase I and II data reported in.....
Original Article: Immatics' vaccine prolongs survival in renal cell cancer
More From BioPortfolio on "Immatics' vaccine prolongs survival in renal cell cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
